About Afferent Pharmaceuticals
Afferent Pharmaceuticals is a company based in San Mateo (United States) founded in 2009 was acquired by Merck in June 2016.. Afferent Pharmaceuticals has raised $78.15 million across 3 funding rounds from investors including Merck, Fidelity Investments and New Leaf Venture Partners. The company has 5 employees as of December 31, 2015. Afferent Pharmaceuticals offers products and services including Medicines, Vaccines, and Patient Assistance Programs. Afferent Pharmaceuticals operates in a competitive market with competitors including Flexion Therapeutics, Eliem Therapeutics, Zogenix, Heron Therapeutics and Ethypharm, among others.
- Headquarter San Mateo, United States
- Employees 5 as on 31 Dec, 2015
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Afferent Pharmaceuticals, Inc.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Afferent Pharmaceuticals
Afferent Pharmaceuticals offers a comprehensive portfolio of products and services, including Medicines, Vaccines, and Patient Assistance Programs. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Treatments for diseases like oncology and infections
Preventive solutions against infectious diseases
Financial aid for accessing medications
Funding Insights of Afferent Pharmaceuticals
Afferent Pharmaceuticals has successfully raised a total of $78.15M across 3 strategic funding rounds. The most recent funding activity was a Series C round of $55 million completed in July 2015. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 3
- Last Round Series C — $55.0M
-
First Round
First Round
(30 Oct 2009)
- Investors Count 9
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2015 | Amount | Series C - Afferent Pharmaceuticals | Valuation |
investors |
|
| Dec, 2009 | Amount | Series A - Afferent Pharmaceuticals | Valuation | Third Rock Ventures , Domain Associates |
|
| Oct, 2009 | Amount | Seed - Afferent Pharmaceuticals | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Afferent Pharmaceuticals
Afferent Pharmaceuticals has secured backing from 10 investors, including institutional and venture fund investors. Prominent investors backing the company include Merck, Fidelity Investments and New Leaf Venture Partners. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Stage-agnostic investments in US life sciences are managed.
|
Founded Year | Domain | Location | |
|
Venture capital funding is provided to early-stage life science companies.
|
Founded Year | Domain | Location | |
|
Life science & tech focused VC firm investing in the US
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Afferent Pharmaceuticals
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Afferent Pharmaceuticals
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Afferent Pharmaceuticals Comparisons
Competitors of Afferent Pharmaceuticals
Afferent Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Flexion Therapeutics, Eliem Therapeutics, Zogenix, Heron Therapeutics and Ethypharm, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Developer of therapies for the treatment of musculoskeletal disorders
|
|
| domain | founded_year | HQ Location |
Develops antibody-based treatments for autoimmune and inflammatory disorders.
|
|
| domain | founded_year | HQ Location |
Drug delivery systems for CNS disorders and pain are developed.
|
|
| domain | founded_year | HQ Location |
Reformulated injectables for chemotherapy side effects and pain are developed.
|
|
| domain | founded_year | HQ Location |
Therapies for pain and addiction treatment are developed.
|
|
| domain | founded_year | HQ Location |
Therapeutics for pain management are developed with abuse-deterrent designs.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Afferent Pharmaceuticals
Frequently Asked Questions about Afferent Pharmaceuticals
When was Afferent Pharmaceuticals founded?
Afferent Pharmaceuticals was founded in 2009.
Where is Afferent Pharmaceuticals located?
Afferent Pharmaceuticals is headquartered in San Mateo, United States. It is registered at San Mateo, California, United States.
Is Afferent Pharmaceuticals a funded company?
Afferent Pharmaceuticals is a funded company, having raised a total of $78.15M across 3 funding rounds to date. The company's 1st funding round was a Seed of $150K, raised on Oct 30, 2009.
How many employees does Afferent Pharmaceuticals have?
As of Dec 31, 2015, the latest employee count at Afferent Pharmaceuticals is 5.
What does Afferent Pharmaceuticals do?
Afferent Pharmaceuticals was founded in 2009 as a clinical-stage biopharmaceutical company based in San Mateo, United States. Small molecule compounds targeting P2X3 receptors are developed for chronic pain, respiratory, and urological conditions. The pipeline includes AF-219, applied to osteoarthritis pain, treatment-refractory chronic cough, and interstitial cystitisbladder pain syndrome, along with AF-220 as a second-generation P2X3 antagonist.
Who are the top competitors of Afferent Pharmaceuticals?
Afferent Pharmaceuticals's top competitors include Flexion Therapeutics, Cara Therapeutics and Satsuma Pharmaceuticals.
What products or services does Afferent Pharmaceuticals offer?
Afferent Pharmaceuticals offers Medicines, Vaccines, and Patient Assistance Programs.
Who are Afferent Pharmaceuticals's investors?
Afferent Pharmaceuticals has 10 investors. Key investors include Merck, Fidelity Investments, New Leaf Venture Partners, Tekla Capital Management, and Jennison Associates.